Division of Infectious Diseases

Pharm to Exam Table: Doravirine DRIVES the way to more ART options

The Department of Health and Human Services HIV guidelines panel currently recommends antiretroviral therapy (ART) consisting of two nucleoside reverse transcriptase inhibitors plus an integrase inhibitor for most treatment naïve HIV infected individuals1.  Prior to the advent of integrase inhibitors, the utilization of non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens had been common.   Both efavirenz and rilpivirine had been commonly used although both NNRTI’s present… Continue Reading

Update for HIV Care Providers and Educators Revived and Reinvigorated!

Content written by Nikki Regan, APRN After a several year hiatus, the UNMC HIV Update conference was back and better than ever.  The conference planning committee at the UNMC/Nebraska Medicine Specialty Care Clinic started organizing this event over a year ago.  “The interest was definitely there,” said Ann Fitzgerald, APRN at the clinic and AIDS Education and Training Program Director for Nebraska. “In the past… Continue Reading

At UNMC, ID fellows learn HIV from the experts

Over the course of their training, fellows in the UNMC’s Division of Infectious Diseases will receive dedicated clinical and didactic training in the area of HIV alongside faculty with expertise in the HIV clinical care and research. Clinical Training: Fellows will have their continuity clinic at UNMC’s HIV clinic one half day each week. The UNMC HIV Program is a regional leader in HIV care… Continue Reading

Ending the AIDS epidemic with 90-90-90…Have YOU been tested?

Today is National HIV Testing Day, and one of the most fulfilling conversations to have with persons living with HIV (PLWH) is to share that since the 1980’s, we have made significant progress in the management of the AIDS epidemic. FDA approval of 27 antiretrovirals and 20 fixed dose combination antiretrovirals, increased HIV testing campaigns and funding for HIV care through the Ryan White Comprehensive AIDS Resource… Continue Reading

Pharm to Exam Table: Monoclonal Antibodies Make Their Way into HIV Treatment

Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Trogarzo® (ibalizumab-uiyk), a new monoclonal antibody treatment approved for multi-drug resistant HIV-1  On March 6th 2018, the Food and Drug Administration approved a new monoclonal antibody called ibalizumab-uiyk, marketed under the tradename Trogarzo®. Ibalizumab-uiyk (IBA) is an intravenous treatment administered every two weeks. It is intended for use in combination with other antiretrovirals (in an optimized background regimen), for… Continue Reading

EMET Student Profile – Rohan Khazanchi, M1

Tell us about the position you are starting? I will be joining the HIV Clinic over the next four years as a new HIV Enhanced Medical Education Track (EMET) student. Being in a longitudinal program like this means I will be returning to the HIV clinic throughout my medical training to learn about management of patients with HIV and work on an independent research project…. Continue Reading

UNMC ID Welcomes New M1 Enhanced Medical Education Track Students

The UNMC College of Medicine offers a unique Enhanced Medical Education Track (EMET) program which provides an opportunity for medical students to delve into particular disciplines of interest in the field of medicine throughout their four year degree program. Track students attend seminars, preceptorships and complete a research project culminating in a poster or conference presentation. More information about the EMET program can be found here…. Continue Reading

Pharm to Exam Table: Meet Biktarvy, the Newest of the Antiretroviral Family!

Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Biktarvy, a new co-formulated integrase inhibitor-based treatment approved for HIV On February 7th 2018, the Food and Drug Administration approved a new combination antiretroviral drug called Biktarvy®(1). Biktarvy® (B/F/TAF) is a single-tablet, once daily regimen containing the novel integrase strand transfer inhibitor bictegravir coformulated with emtricitabine and tenofovir alafenamide (1). Current HIV guidelines recommend integrase strand transfer inhibitor… Continue Reading

Josh Havens, PharmD on “Why I Love ID”

Why I Love ID:  Infectious diseases, in general, is quite interesting, but I can really only speak from an HIV perspective. My initial career interests were not in infectious diseases and it was not until I threw myself into this niche world of HIV that I started to recognize a true affinity toward the field.  It is rare to find an infection that is such… Continue Reading

World Social Work Day – Meet our HIV Case Management Team

The official theme for Social Work Month in March 2018 is “Social Workers: Leaders. Advocates. Champions.” Social workers are the glue that keeps clinical practices together as we balance the need to care for patients with the socioeconomic needs of the individual patients. At the Specialty Care Center, our Case Management team works tirelessly to ensure that patients’ needs are met; they enroll patients in insurance, review… Continue Reading